Medisonal

Medisonal Ltd is a group of specialised companies dedicated to addressing the unmet clinical needs of patients. This has been achieved with the development and offering of effective tools and an innovative platform for physicians to share their expert knowledge. Through its strategic partnership with PCCA, Medisonal provides access to a plethora of licensed and unlicensed medications, enabling physicians to provide the care that their patients deserve.

The Medisonal Institute of Education (MIE) is constantly expanding its offering; providing numerous courses for doctors, healthcare professionals, and patients with regards to various medical conditions and treatments, including CPD accredited courses on CBPMs and psychedelics.

One of Medisonal's significant accomplishments is the development of the M3 platform. The first platform in the UK designed to streamline the prescription process for unlicensed medicine. Currently, over 200 healthcare professionals use the M3 platform, and the numbers are continually growing. M3 is also adaptable to other markets, and healthcare professionals from various countries are joining.

The Medisonal Clinic is expected to launch in Q2 2023.

Medisonal conducts extensive research and development activities and has its own R&D arm, "Liberum Health," which is working on innovative drug delivery systems. This new intellectual property has the potential to significantly improve the application of licensed and unlicensed medications, with a focus on women's health.

In 2022, Medisonal Central Europe was established, giving Medisonal a presence in European markets. It also provides a platform for the UK and the EU to exchange best practices. Medisonal France and Medisonal Scandinavia are expected to launch in 2023.